Strong trader consensus against a hantavirus vaccine approval by end of 2026 stems from the absence of any candidates in Phase 3 trials and the extended timelines required for safety, immunogenicity, and efficacy data in humans. Multiple DNA, mRNA, and recombinant approaches remain in preclinical or early Phase 1 stages, with recent animal studies showing neutralizing antibody responses but no human efficacy results. Historical patterns for rare zoonotic pathogens like hantavirus, combined with limited commercial incentives and the need for large-scale field trials, reinforce the 94.5% implied probability for “No.” A sudden outbreak-driven emergency authorization or accelerated regulatory pathway could theoretically shift outcomes, though current surveillance data and development pipelines make such acceleration improbable within the remaining months.